RhumbLine Advisers
SION

RhumbLine Advisers’s Sionna Therapeutics SION Stock Holding History

RhumbLine Advisers’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$981K Buy
22,309
+4,001
+22% +$160K ﹤0.01% 2327
2026
Q1 		$734K Buy
18,308
+614
+3% +$23.4K ﹤0.01% 2368
2025
Q4 		$728K Buy
17,694
+454
+3% +$17.2K ﹤0.01% 2413
2025
Q3 		$507K Sell
17,240
-430
-2% -$9.36K ﹤0.01% 2691
2025
Q2 		$307K Buy
+17,670
New +$232K ﹤0.01% 2974

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

RhumbLine Advisers's SION Position: Q2 2026 in Review

RhumbLine Advisers increased its Sionna Therapeutics (SION) stake by 22% in Q2 2026, buying an estimated $160K and bringing the position to 22,309 shares worth $981K. The position accounts for ﹤0.01% of the portfolio, ranked #2327.

RhumbLine Advisers first reported a position in SION in Q2 2025 and has held it in 5 quarters since. 146 funds tracked by Wall St. Rank hold SION as of Q2 2026.

  • RhumbLine Advisers held 22,309 shares of Sionna Therapeutics worth $981K as of Q2 2026.
  • RhumbLine Advisers bought 4,001 Sionna Therapeutics shares in Q2 2026, an estimated $160K.
  • Sionna Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2327 holding.
  • RhumbLine Advisers first reported a position in Sionna Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 146 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.